"We have now proven that, in some people, pre-existing T cell memory against common cold coronaviruses can cross-recognise SARS-CoV-2, down to the exact molecular structures," said Daniela Weiskopf, a co-author of the study from LJI.
"This could help explain why some people show milder symptoms of disease while others get severely sick," Weiskopf said.
Alessandro Sette, another co-author of the study from LJI, noted that the reactivity of the immune system may translate to different degrees of protection.
"Having a strong T cell response, or a better T cell response may give you the opportunity to mount a much quicker and stronger response," Sette said.
An earlier study by Sette and his team had shown that 40 to 60 per cent of people who were never exposed to the novel coronavirus SARS-CoV-2 had T cells that reacted to the virus.
According to the study, the immune systems in these individuals recognised fragments of the virus it had never seen before -- a finding which was also reported among people in the Netherlands, Germany, Singapore, and the UK.
In the current research, the scientists assessed samples collected from study participants who had never been exposed to SARS-CoV-2.
They defined the exact parts of the virus that are responsible for the cross-reactive T cell response.
Their analysis showed that unexposed individuals can produce a range of memory T cells that are equally reactive against SARS-CoV-2, and four types of common cold coronaviruses.
Based on the finding, the scientists said fighting off a common cold coronavirus could teach the T cell compartment to recognise some parts of SARS-CoV-2 as well.
They believe this process provides evidence for the hypothesis that common cold viruses can, in fact, induce cross-reactive T cell memory against SARS-CoV-2.
"We knew there was pre-existing reactivity, and this study provides very strong direct molecular evidence that memory T cells can 'see' sequences that are very similar between common cold coronaviruses and SARS-CoV-2," Sette said.
The scientists found that while some cross-reactive T cells targeted the SARS-CoV-2's spike protein -- the region of the virus that recognises and binds to human cells -- pre-existing immune memory was also directed to other SARS-CoV-2 proteins.
Sette noted that the finding is relevant since most vaccine candidates target the spike protein.
The findings, according to the researchers, suggest the hypothesis that inclusion of additional SARS-CoV-2 targets might enhance the potential to take advantage of this cross reactivity, and could further enhance vaccine potency.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.